AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15997963 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 90
Study 12748832 — intervention group
Group type: COMPARATOR
Intervention: Perfusion scintigrams alone
Number of subjects: 102
Study 12748832 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion scintigrams plus one ventilation image (posterior view)
Number of subjects: 102
Study 12748832 — intervention group
Group type: EXPERIMENTAL
Intervention: All perfusion and ventilation images
Number of subjects: 102
Study 10546188 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether (3.6 mg/kg on day 1, 1.6 mg/kg for the next 4 days)
Number of subjects: 84
Study 10546188 — intervention group
Group type: COMPARATOR
Intervention: Quinine (1.6 mg/kg for the first 4 hours, 8 mg every 8 hours for the next 3 days)
Number of subjects: 84
Study 8912545 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative estrogen receptor (ER) detection by immunohistochemistry (IHC)
Number of subjects: 128
Study 8912545 — intervention group
Group type: EXPERIMENTAL
Intervention: Mib1-positive tumour cells (> 40%)
Number of subjects: 128
Study 8912545 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial tumour size less than 4 cm
Number of subjects: 128
Study 8912545 — intervention group
Group type: EXPERIMENTAL
Intervention: c-erbB-2 overexpression detected by IHC
Number of subjects: 128
Study 1928529 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment unit (GAU)
Number of subjects: 0
Study 1928529 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 6120706 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel containing fomocaine and diphenhydramine
Number of subjects: 16
Study 6120706 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-erythema model
Number of subjects: 16
Study 31782408 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex)
Number of subjects: 54
Study 31782408 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (Oxy)
Number of subjects: 54
Study 31782408 — intervention group
Group type: COMPARATOR
Intervention: Control (I/R)
Number of subjects: 54
Study 28968224 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching by retired physicians
Number of subjects: 120
Study 28968224 — intervention group
Group type: COMPARATOR
Intervention: No coaching (control group)
Number of subjects: 120
Study 24732714 — intervention group
Group type: EXPERIMENTAL
Intervention: Hashimoto thyroiditis patients
Number of subjects: 44
Study 24732714 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 44
Study 23446109 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 to 40 mg/day)
Number of subjects: 88
Study 23446109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 21062669 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oral estradiol valerate
Number of subjects: 53
Study 21062669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 19608684 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct sequencing alone or in combination with denaturing high-performance liquid chromatography
Number of subjects: 200
Study 19608684 — intervention group
Group type: EXPERIMENTAL
Intervention: Allele-specific oligonucleotide polymerase chain reaction techniques
Number of subjects: 200
Study 19608684 — intervention group
Group type: EXPERIMENTAL
Intervention: Allele-specific oligonucleotide polymerase chain reaction
Number of subjects: 200
Study 19608684 — intervention group
Group type: COMPARATOR
Intervention: Denaturing high performance liquid chromatography combined with direct sequencing
Number of subjects: 200
Study 15709655 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-Doppler perfusion monitoring (LDPM) for measuring post-occlusive reactive hyperemia (PORH)
Number of subjects: 0
Study 15709655 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer program developed for fitting the model to measured data
Number of subjects: 0
Study 12535284 — intervention group
Group type: EXPERIMENTAL
Intervention: Soaps containing betaine
Number of subjects: 28
Study 12535284 — intervention group
Group type: COMPARATOR
Intervention: Soaps without betaine
Number of subjects: 28
Study 12535284 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing concentrations of betaine
Number of subjects: 28
Study 12535284 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive methods
Number of subjects: 28
Study 10798801 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) for predicting low risk of lymph node spread (LNS)
Number of subjects: 409
Study 10798801 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) for predicting capsular penetration (CP)
Number of subjects: 409
Study 8869047 — intervention group
Group type: EXPERIMENTAL
Intervention: AJI software
Number of subjects: 26
Study 8869047 — intervention group
Group type: COMPARATOR
Intervention: APIS software
Number of subjects: 26
Study 1676117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (15 mg/kg daily by mouth, average daily dose 1000 mg)
Number of subjects: 152
Study 1676117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 1676117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 152
Study 1676117 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin and Placebo
Number of subjects: 152
Study 6219690 — intervention group
Group type: EXPERIMENTAL
Intervention: 13‐cis‐retinoic acid (0.5 mg/kg b.w.)
Number of subjects: 76
Study 29757354 — intervention group
Group type: EXPERIMENTAL
Intervention: Distractor group (operation with a distractor)
Number of subjects: 230
Study 29757354 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily exercises)
Number of subjects: 230
Study 29757354 — intervention group
Group type: EXPERIMENTAL
Intervention: Distractor group
Number of subjects: 230
Study 29757354 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 230
Study 27834736 — intervention group
Group type: EXPERIMENTAL
Intervention: CoDuSe group exercise programme (14 supervised 60-minute sessions over 7 weeks)
Number of subjects: 48
Study 27834736 — intervention group
Group type: EXPERIMENTAL
Intervention: CoDuSe group exercise programme
Number of subjects: 48
Study 27834736 — intervention group
Group type: COMPARATOR
Intervention: Control group (late start of exercise)
Number of subjects: 48
Study 25689540 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum allowable distance policy (500 ft between tobacco outlets)
Number of subjects: 0
Study 25689540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy and near-schools ban
Number of subjects: 0
Study 25078976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin CR (330 mg) administered with food (800-1,000 calorie medium-fat breakfast)
Number of subjects: 128
Study 25078976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin CR (330 mg) administered fasted
Number of subjects: 128
Study 25078976 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin IR (300 mg) administered with food
Number of subjects: 128
Study 25078976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin CR (330 mg) administered with food
Number of subjects: 128
Study 25078976 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin IR (300 mg) administered fasted
Number of subjects: 128
Study 22663901 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for psychosis (CBTp)
Number of subjects: 80
Study 22663901 — intervention group
Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 80
Study 19470889 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice daily
Number of subjects: 1715
Study 19470889 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg once daily
Number of subjects: 1715
Study 19470889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1715
Study 17293364 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + infliximab (IFX)
Number of subjects: 244
Study 17293364 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent conventional DMARDs (sulfasalazine, leflunomide, hydroxychloroquine, prednisone)
Number of subjects: 244
Study 17293364 — intervention group
Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 244
Study 16433247 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (10 nM, 1 M, and 100 M)
Number of subjects: 121
Study 16433247 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy
Number of subjects: 121
Study 16433247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 12723391 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitation practice
Number of subjects: 95
Study 10389797 — intervention group
Group type: EXPERIMENTAL
Intervention: Chilled 5% albumin (5 mL/kg at 1‐6 degrees C) infused over 5 min
Number of subjects: 0
Study 10389797 — intervention group
Group type: EXPERIMENTAL
Intervention: Chilled 5% albumin (5 mL/kg at 1‐6 degrees C) infused over 30 min
Number of subjects: 0
Study 8546552 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiographs screening
Number of subjects: 1065
Study 8546552 — intervention group
Group type: COMPARATOR
Intervention: Normal radiographs
Number of subjects: 1065
Study 1647685 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino Acid Mix (AA mix)
Number of subjects: 7
Study 1647685 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-Chain Amino Acids (BCAA)
Number of subjects: 7
Study 1647685 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AA mix and BCAA
Number of subjects: 7
Study 6196821 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal lavage with 500,000 KIU aprotinin every 2 h
Number of subjects: 55
Study 6196821 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal lavage without aprotinin
Number of subjects: 55
Study 6196821 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study 31411351 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FI O2 (30% air-oxygen mixture)
Number of subjects: 86
Study 31411351 — intervention group
Group type: COMPARATOR
Intervention: High FI O2 (100% oxygen during preoxygenation and recruitment maneuver, 60% air-oxygen mixture during mechanical ventilation)
Number of subjects: 86
Study 30309382 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Messaging Service (SMS) intervention
Number of subjects: 104
Study 30309382 — intervention group
Group type: COMPARATOR
Intervention: Non-SMS control group
Number of subjects: 104
Study 26876911 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet prime (cover of a dieting magazine) in Experiment 1
Number of subjects: 701
Study 26876911 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet prime (diet-related commercials) in Experiment 2
Number of subjects: 701
Study 26876911 — intervention group
Group type: COMPARATOR
Intervention: Control (no diet prime) in both experiments
Number of subjects: 701
Study 25311633 — intervention group
Group type: COMPARATOR
Intervention: Chocolate consumption <1/month
Number of subjects: 20278
Study 25311633 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate consumption 1-3/week
Number of subjects: 20278
Study 25311633 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate consumption 2-4/week
Number of subjects: 20278
Study 25311633 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate consumption 5+/week
Number of subjects: 20278
Study 25311633 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate consumption 5+/week in men with BMI <25 kg/m2
Number of subjects: 20278
Study 25311633 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate consumption 5+/week in men with BMI 25+ kg/m2
Number of subjects: 20278
Study 22075619 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional computer model
Number of subjects: 40
Study 22075619 — intervention group
Group type: COMPARATOR
Intervention: Two-dimensional images
Number of subjects: 40
Study 21038647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongfu Granule (TFG), 1 bag, three times per day, for 7 days via oral intake or gastric infusion
Number of subjects: 60
Study 21038647 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered in the same manner as TFG
Number of subjects: 60
Study 17665471 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis Self-Help Course (ASHC)
Number of subjects: 416
Study 17665471 — intervention group
Group type: COMPARATOR
Intervention: Chronic Disease Self-Management Program (CDSMP)
Number of subjects: 416
Study 17665471 — intervention group
Group type: COMPARATOR
Intervention: Comparison between ASHC and CDSMP
Number of subjects: 416
Study 17665471 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ASHC and CDSMP
Number of subjects: 416
Study 16112071 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artemether (6 mg/kg) administered once every 2 weeks for 9-11 doses
Number of subjects: 783
Study 16112071 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered once every 2 weeks for 9-11 doses
Number of subjects: 783
Study 12140351 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg twice a day)
Number of subjects: 140
Study 10206298 — intervention group
Group type: COMPARATOR
Intervention: Cytokeratin 19 mRNA
Number of subjects: 48
Study 10206298 — intervention group
Group type: COMPARATOR
Intervention: Cytokeratin 20 mRNA
Number of subjects: 48
Study 10206298 — intervention group
Group type: COMPARATOR
Intervention: Guanylyl cyclase C (GCC) mRNA
Number of subjects: 48
Study 7750316 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (0.1 mg/kg bolus, continuous infusion at 2 micrograms/kg/min during surgery, and 30 mg nasogastric tube every 8 hours)
Number of subjects: 23
Study 7750316 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 23
Study 7750316 — intervention group
Group type: COMPARATOR
Intervention: Nontreated group (control)
Number of subjects: 23
Study 2308471 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg O.D.
Number of subjects: 14
Study 2308471 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg B.I.D.
Number of subjects: 14
Study 2308471 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.6 mg/kg O.D.
Number of subjects: 14
Study 2308471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 381220 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirbuterol 400 microgram
Number of subjects: 12
Study 381220 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 microgram
Number of subjects: 12
Study 381220 — intervention group
Group type: COMPARATOR
Intervention: Pirbuterol 200 microgram
Number of subjects: 12
Study 381220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29316983 — intervention group
Group type: EXPERIMENTAL
Intervention: Urogenital schistosomiasis prevalence and intensity of S. haematobium infection evaluated microscopically by two filtrations of urine.
Number of subjects: 19039
Study 29316983 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy infections of S. haematobium.
Number of subjects: 19039
Study 29316983 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of infection rates between males and females.
Number of subjects: 19039
Study 29316983 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence and intensity of infection in adolescents vs first-year students.
Number of subjects: 19039
Study 29316983 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence and intensity of infection in adults.
Number of subjects: 19039
Study 29316983 — intervention group
Group type: EXPERIMENTAL
Intervention: Community knowledge about schistosomiasis.
Number of subjects: 19039
Study 29316983 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk behavior related to schistosomiasis.
Number of subjects: 19039
Study 26720295 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART Pathway
Number of subjects: 282
Study 25489844 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir (valG) for 14 days pretransplant
Number of subjects: 17
Study 25489844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 25489844 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir (valG)
Number of subjects: 17
Study 25489844 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir (valG) and routine posttransplant viral prophylaxis
Number of subjects: 17
Study 22950654 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7687 (5-60 mg, oral administration)
Number of subjects: 80
Study 22950654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 20107765 — intervention group
Group type: EXPERIMENTAL
Intervention: Pmus(PVI)
Number of subjects: 11
Study 20107765 — intervention group
Group type: EXPERIMENTAL
Intervention: Various methods of calculation
Number of subjects: 11
Study 20107765 — intervention group
Group type: EXPERIMENTAL
Intervention: Assist levels (30%, 50%, 70%)
Number of subjects: 11
Study 18854568 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y‐ibritumomab tiuxetan consolidation
Number of subjects: 414
Study 18854568 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y‐ibritumomab tiuxetan
Number of subjects: 414
Study 18854568 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (control)
Number of subjects: 414
Study 15698703 — intervention group
Group type: EXPERIMENTAL
Intervention: Method I (measuring the shortest distance between the posterior lip of the distal tibia and the talar dome)
Number of subjects: 0
Study 15698703 — intervention group
Group type: COMPARATOR
Intervention: Other measurement techniques (not specified)
Number of subjects: 0
Study 12699264 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative medical therapy (progestins with or without estrogens)
Number of subjects: 0
Study 12699264 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressing ovarian activity postoperatively
Number of subjects: 0
Study 12699264 — intervention group
Group type: EXPERIMENTAL
Intervention: Various drugs used before or after surgery
Number of subjects: 0
Study 10760344 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened nitroglycerin HUT
Number of subjects: 137
Study 10760344 — intervention group
Group type: COMPARATOR
Intervention: Conventional nitroglycerin HUT
Number of subjects: 137
Study 10760344 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened nitroglycerin HUT (first test)
Number of subjects: 137
Study 10760344 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened nitroglycerin HUT (second test)
Number of subjects: 137
Study 10760344 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (shortened nitroglycerin HUT)
Number of subjects: 137
Study 8869864 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg twice daily (high dose)
Number of subjects: 83
Study 8869864 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 5 mg twice daily (low dose)
Number of subjects: 83
Study 1504052 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) with recombinant interferon-beta (IFN-beta)
Number of subjects: 49
Study 1504052 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-2 (IL-2) without recombinant interferon-beta (IFN-beta)
Number of subjects: 49
Study 6402342 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release buccal nitroglycerin (BNTG)
Number of subjects: 16
Study 6402342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30818032 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) plus Treatment as Usual (TAU)
Number of subjects: 70
Study 30818032 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 70
Study 29324303 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg (first-line)
Number of subjects: 730
Study 29324303 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant 250 mg (first-line)
Number of subjects: 730
Study 29324303 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg (second-line)
Number of subjects: 730
Study 29324303 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant 250 mg (second-line)
Number of subjects: 730
Study 27871510 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.5 mg IV bolus)
Number of subjects: 114
Study 27871510 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (IV bolus)
Number of subjects: 114
Study 25050363 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy
Number of subjects: 60
Study 25050363 — intervention group
Group type: COMPARATOR
Intervention: Self-control of parafunctional habits (Control)
Number of subjects: 60
Study 21471025 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1-2 μg/kg/h intravenously)
Number of subjects: 160
Study 21471025 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (0.1-0.2 mg/kg/h intravenously)
Number of subjects: 160
Study 19852540 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO2, 60 minutes of HBO(2) at 1.5 ATA
Number of subjects: 69
Study 19852540 — intervention group
Group type: EXPERIMENTAL
Intervention: NBH, 3 hours of 100% fraction of inspired oxygen at 1 ATA
Number of subjects: 69
Study 19852540 — intervention group
Group type: COMPARATOR
Intervention: Control, standard care
Number of subjects: 69
Study 18395326 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily vardenafil 10mg for 12 weeks
Number of subjects: 0
Study 18395326 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily vardenafil 10mg for 24 weeks
Number of subjects: 0
Study 18395326 — intervention group
Group type: COMPARATOR
Intervention: On-demand vardenafil 10mg for 24 weeks
Number of subjects: 0
Study 18395326 — intervention group
Group type: COMPARATOR
Intervention: Once-daily vardenafil 10mg (12 weeks) vs On-demand vardenafil (24 weeks) after washout
Number of subjects: 0
Study 16164192 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy (PTX)
Number of subjects: 10
Study 16164192 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-Oxacalcitoriol (OCT)
Number of subjects: 10
Study 14534517 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (7.5 mg intravenous infusion over 3 hours)
Number of subjects: 12
Study 14534517 — intervention group
Group type: COMPARATOR
Intervention: Quinidine (800 mg, placebo-controlled)
Number of subjects: 12